Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved ...

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for ...

Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...

(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...